THROMBO-EMBOLIC RISK IN HIGH ESTROGENIC PHASE OF NORMAL MENSTRUAL CYCLE IN HEALTHY WOMEN.
Objective: This study is conducted to compare the risk of thrombo-embolism during different phases of menstrual cycles.
Methodology:105 healthy premenopausal unmarried females of 18 -21 years with a history of previous three normal menstrual cycles and 32 age matched male volunteers were recruited in the study. The phase of menstrual cycle of female volunteers was established by taking menstrual history. Bleeding time was determined by Duke's method.
Results: Bleeding time in 105 females was 73.031.89 Seconds and in 32 males was 69.334.94 Seconds which were not significantly different statistically (p=0.063). Among females, 69 volunteers were in follicular phase of their hormonal cycle. Bleeding time in 29 females in early follicular phase was 70.863.38 Seconds and 40 females in late follicular phase was 68.254.03 Seconds. Statistically significant difference was not seen (p=0.095) when the two phases were compared. Bleeding time is not found to be reduced in late follicular phase as compared to early follicular phase, even high concentration of estrogen is present in the body in this phase as per normal menstrual physiology.
Conclusion: High Estrogen in normal menstrual cycle does not increase thrombo-embolic risk in healthy women.
Key Words: Estrogen, Bleeding time, Thrombo-embolism.
Estrogen is one of the important female steroid sex hormones. Incidences of thromboembolism in women taking estrogen support the fact that there exists an increased risk of thromboembolism in such women1. Many causes are associated with it like it increases pro-coagulants2, neutralizes anti coagulants like anti-thrombin III3, increases clotting factor4,5 and decreases Nitric oxide6. However the protective role of estrogen against thrombogenesis has also been identified in many studies but without clear cascade7,8. Our study is designed to assess the role of high endogenous estrogen during normal menstrual cycle for increasing the risk of thromboembolism. We compared the bleeding time in early and late follicular phases because estrogen levels are relatively very low and very high9 during these phases respectively.
APPT and PTT were not considered because of limited role of these two parameters10,11 as compared to bleeding time in platelets adhesions, activation and aggregation at the sites of vascular disruption12.
150 male and female volunteers of an undergraduate class of Karachi Medical and Dental College were randomly recruited from Jan 01 till Jan 15, 2014. Study was explained properly to them. The plan was approved by ethical committee of the institute.
Criteria of inclusion was: absence of any chronic illness or bleeding disorder, no drug therapy in the last 15 days, abstinence from consumption of flavonoid rich foods or beverages since 24 hours and three consecutive previous normal menstrual cycles (28 2 days) in case of females while any congenital anomaly, skin disease effecting the test site and any addiction was the criteria for exclusion. 137 volunteers were eligible after consent to find bleeding time by Duke's method13.
Stage of menstrual cycle of each female was determined by a structured interview. The early follicular phase was designated from day 1 after menstruation to day 7 while late follicular phase from day 8 today 15. Only 69 out of 105 females were found to be in follicular phase while the remaining were excluded from further stages of this study.
SPSS version 16.0 was used for statistical analysis.
A total of 137 unmarried volunteers took part in the study in whom 32 were males and 105 were females. The mean age was 20.12 years with an age range of 18 to 21 years. A total of 69 females were in follicular phase of their menstrual cycle Table 1.
Table 2 shows the comparison of bleeding times in early and the late follicular phases in 69 females. Mean bleeding time in 29 female in early follicular phase was 70.863.38 Seconds (MeanSEM), while in 40 female in late follicular was 68.254.03 Seconds (MeanSEM).No statistically significant difference (pgreater than 0.05) is found between them.
Conflicting data exists in literature regarding the effect of estrogen on cardiovascular system. At one side estrogen is found to be thrombogenic by cohorts of the patients using contraceptive pills or receiving hormonal replacement therapy1,2 which is also supported by the fact that a number of pathways are altered by estrogen that effect the cardiovascular system14,15 and many changes in factors influencing coagulation have been reported including increased circulating levels of factors II, VII, IX and X and decreased anti-thrombin III pathway due to hepatic effects16.
At other side it proves to be non thrombogenic7,8 because premenopausal women have less chances of developing thromboembolism due to high estrogen than men of same age while post-menopausal females equalizes their risk with males of same age due to low estrogen17 which is also supported by the fact that estrogen has found to maintain vascular health by inducing prostacyclin and nitric oxide synthase through estrogen alpha receptors17,18. Our study does not support thrombogenic nature of estrogen. An initial support comes from insignificant difference (pgreater than 0.05) in the bleeding time of male having low estrogen and female having high estrogen.
But the strong support comes by comparing the bleeding times in early having Low estrogen16 and late having high estrogen 16follicular phases of menstrual cycle of normal healthy females rejecting the hypothesis that risk of thromboembolism should be increased during the phase of menstrual cycle in which body has relatively high estrogen. However the thrombogenic nature cannot be easily overlooked simply by these results because it is supported by a number of studies mentioned earlier. The hypothesis that the endogenous estrogen act in equilibrium with other components of coagulation adjusted as per demand of the body created with high level of this hormone while exogenous estrogen does not exist in equilibrium with these components, can accommodate both thrombogenic and non thrombogenic nature of estrogen.
One of the recent studies support this through the assessment of Activated Protein C resistance which is found to be one of the major factors that contributes in developing Deep Venous Thrombosis in both oral contraceptive and estrogen replacement therapy users19and concluded that normal physiological levels of estrogen during menstrual cycle don't alter the Activated Protein C sensitivity20. Considering the receptor regulation of estrogen also support this hypothesis. It is well known that the increased levels of steroid hormones down regulate their own receptors21 therefore, it can be considered that estrogen receptors are down regulated by persistently increased level of estrogen in women using contraceptives. Estrogen a receptors are mainly present on vessels endothelial cells therefore when there are less a receptors there may be less NO and prostacyclin produced that may increase risks of thromboembolism in premenopausal women.
Although the levels of serum NO and prostacyclin in oral contraceptive users are not directly measured but this fact is supported by a study in which estrogen present in contraceptives significantly decrease prostacyclin and NO levels than estrogen at physiological levels22. Similarly the methylation associated inactivation of estrogen a receptors seems to be the main cause of thromboembolism in post-menopausal aged women on HRT23,24.
Table 1: Bleeding time in both genders (n=137).
Table 2: Bleeding time in females in Early and Late Follicular Phase (n=69).
It is concluded that endogenous estrogen does not increase the risk of thrombo-embolism in healthy women.
1. Gomes MPV, Deitcher SR. Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy; Arch Intern Med 2004; 164:1965-76.
2. Hodges RM.The effects of oral estrogen-progestin compounds on blood coagulation factors. Int J Fertil 1968; 13:349-53.
3. Nagasawa H, Kim BK, Steiner M, Baldini MG. Inhibition of thrombin-neutralizing activity of antithrombin III by steroid hormones. Thromb Haemost 1982; 47:157-61.
4. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Int J Fertil 2000; 13:349-53
5. Bertina RM. Elevated Clotting Factor Levels and Venous Thrombosis, Pathophysiol Haemost Thromb 2004; 33: 399-400
6. Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost 2003; 1:1183-8.
7. Butkiewicz AM, Kemona H, Dymicka-Piekarska V, Matowicka-Karma J. Does menopause affect thrombocytopoiesis and platelet activation Przegel Lek 2006; 63:1291-3.
8. Valera MC, Gratacap MP, Gourdy P, Lenfant F, Cabou C, Toutain CE, et al. Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor a. Blood 2012; 120:1703-12.
9. Chrousos GP. The gonadal hormones and Inhibitors. In: Katzung BG, Ed. Basic and Clinical Pharmacology. 10th ed. New York, McGraw Hill; 2007:653-82.
10. Mitsuguro M, Okamoto A, Shironouchi Y, Sano M, Miyata S, Neki R, et al. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol 2015;101:119-25.
11. Shontz R, Karuparthy V, Temple R, Brennan TJ. Prevalence and risk factors predisposing to coagulopathy in patients receiving epidural analgesia for hepatic surgery. Reg Anesth Pain Med 2009; 34:308-11.
12. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis.Am J Cardiovasc Drugs 2005; 5:399-408.
13. Ramnik S. Textbook of medical laboratory technology. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2006:123-88.
14. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Kenneth KWU, et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Eng J Med 1993; 328:1069-75.
15. Mendelsohn M.E. The protective effects of estrogen on cardiovascular system. Am J Cardiol 2002; 89:12E-17E.
16. Chrousos GP. The gonadal hormones and Inhibitors. In: Katzung BG, Ed. Basic and Clinical Pharmacology. 10th ed. New York, McGraw Hill; 2007:654-6.
17. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice. Science 2004; 306: 1954-7.
18. Chen Z, Yuhann IS, Galcheva-Gargova Z, Richard H, Karas, Mendelsohn ME, et al. Estrogen receptor a mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103:401-6.
19. Tchaikovski SN, Rosing J. Mechanisms of Estrogen-Induced Venous Thromboembolism. Thrombosis Res 2010; 126: 5-11.
20. Van Rooijen M, Silveira A, Thomassen S, Odeberg J, Hamsten A, et al. APC resistance during the normal menstrual cycle. Thromb Haemost 2007; 98:1246-51.
21. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17b-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence, Mol Cell Biol 2000; 20: 2890-901.
22. Bolego C, Cignarella A, Ruzza R, Zaarour C, Messi E, Zanisi M, et al. Differential effects of lowand high-dose estrogen treatments on vascular responses in female rats. Life Sci 1997; 60:2291-302.
23. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman AW, Sussman MS. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43, 985-91.
24. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-34.
|Printer friendly Cite/link Email Feedback|
|Publication:||Journal of Postgraduate Medical Institute|
|Date:||Sep 30, 2015|
|Previous Article:||EFFECT OF POVIDONE-IODINE IRRIGATION ON POST APPENDECTOMY WOUND INFECTION: RANDOMIZED CONTROL TRIAL.|
|Next Article:||ASSESSMENT OF SERUM CALCIUM AND PHOSPHORUS LEVELS AMONG TRANSFUSION-DEPENDENT BETA THALASSEMIA MAJOR PATIENTS ON CHELATION THERAPY.|